**Abstract**

***Background:*** The pathophysiology underlying major depressive disorder (MDD) remains to a large extent enigmatic. Stress and inflammatory processes can induce MDD and push tryptophan through the kynurenine pathway. This may ultimately result in increased quinolinic acid (QUIN), a neurotoxic metabolite of kynurenine with (N-methyl-D-aspartate receptor (NMDA-R) agonistic properties that has been associated with depressive symptoms^1^ and suicide^2^. Sharing a common precursor, these processes may converge with the predominant serotonin hypothesis of MDD. *Aim:* To investigate the effects of the selective serotonin reuptake inhibitor fluoxetine or the NMDA-R antagonist ketamine on QUIN levels in both brain and plasma in three different rat strains.

***Method:*** The genetic rat model of depression, Flinders Sensitive Line rat and its controls: Flinders Resistant Line and Sprague Dawley rats were used. Male rats aged 9--12 weeks were treated with fluoxetine (160 mg/L drinking water) or ketamine (15 mg/kg, i.p., every 3^rd^ day, which produces a sustained antidepressant-like effect in the forced swim test), or 0.9% saline (vehicle, i.p. every 3^rd^ day) for 14 days. Subsequently, QUIN levels in 8 different brain regions (right and left frontal cortex, hippocampus, hypothalamus, striatum, midbrain, cerebellum, \"rest of brain\") and plasma were measured by liquid-chromatography/mass-spectrometry.

***Results:*** Fluoxetine significantly decreased QUIN in midbrain, cerebellum and rest of brain (by 18--35%) and plasma (29%). There was no effect of ketamine in any brain area or plasma.

***Conclusion:*** At clinically relevant levels of SERT occupancy fluoxetine produce a reduction of the neurotoxic QUIN, whereas ketamine had no effects using an intermittent dosing regimen.
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